Abstracts tagged "BLyS and Lupus"

Abstract Number: 2586 • 2017 ACR/ARHP Annual Meeting
Exposure-Response Modelling and Exposure-Safety Modelling Analyses in Two Phase II Studies of Atacicept in SLE
Orestis Papasouliotis¹, Oezkan Yalkinoglu¹, Cristina Vazquez-Mateo², Stephen Wax³, Amy H. Kao², Peter Chang³, Patricia Fleuranceau-morel² and Lisa Mahnke², ¹Merck KGaA, Darmstadt, Germany, ²EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ³EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), BIllerica, MA
Background/Purpose: Atacicept targets the B-cell stimulating factors BLyS and APRIL, and has been shown to reduce SLE disease activity. Our analyses evaluated the exposure-response and…
Abstract Number: L6 • 2012 ACR/ARHP Annual Meeting
Blisibimod, an Inhibitor of B Cell Activating Factor, in Patients with Moderate-to-Severe Systemic Lupus Erythematosus
Richard A. Furie¹, Morton A. Scheinberg², Gustavo Leon³, Edgar B. Ramiterre⁴, Matthew Thomas⁵, Renee S. Martin⁶ and Michelle Petri⁷, ¹The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, ²Rheumatology Hospital Abreu Sodre Pesquisa Clínica, São Paulo, Brazil, ³Instituto De Ginecologia Y Reproduccion, Lima, Peru, ⁴Brokenshire Memorial Hospital, Davao City, Philippines, ⁵Health and Research Centre, Trivandrum, Kerala, India, ⁶Anthera Pharmaceuticals Inc, Hayward, CA, ⁷Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: To evaluate the efficacy, safety, and tolerability of subcutaneously-administered blisibimod (A-623, AMG 623), an inhibitor of soluble- and membrane-bound B-cell activating factor (BAFF), in patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].